Despite disappointments in the hunt for effective fat-busting drugs, this large and seemingly ever-growing market is encouraging companies to continue to rise to the challenge of a disease that is a host of interacting disorders.
by Melanie A. Senior
Obesity affects more than a fifth of the adult population in the US and Germany, and more than 15% in the UK (see Exhibit 1). Yet it's only in the...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
New CEO Renée Aguiar-Lucander is marking her mark.
Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.
Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.
In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.
Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.
AI-powered drug development was a major topic at the recent Bio Korea meeting, where experts discussed how the technology is changing R&D activities and the challenges being faced by Korean firms as they look to catch up with their global competitors.
